People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Alternative dosing routes, such as rectal and intranasal (IN) routes, have been suggested as options for oral or intravenous administration. Rhinitis and pharmacological agents used for treatment ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

It is a container that holds saline solution which rises the nasal passages. There are various kinds of nasal irrigation ...

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Nasal sprays can treat congestion and other symptoms of seasonal allergies or a cold. They work by delivering a fine mist of medication into your nostrils. Since the lining of your nose is rich with ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression. The drug, SPRAVATO, is made by Johnson & Johnson and was first approved in 2019 for adults ...